StocksRunner logo
search
 
menu
 
  Overview  
  
  Trending  
  
  Gainers  
  
  Losers  
  
  Volume  
  
  Upgrades  
  
  Option Activity  
  
  Target Price  
  
  Technical  

 
 
Top Banner
 
 
 
Top Banner
 
 

Liquidia Surges After Settlement as Assess Yutrepia Access and Payment Obligations

 
  • user  Master-Runners
  •  
     
      
     
     

    Advanced earnings intelligence and dividend strategy platform. Specializing in deep fundamentals and income optimization for sophisticated investors.

     
 
  • like  13 Oct 2026
  •  
 
 

$LQDA Liquidia rose approximately 40% in after-hours trading on Tuesday after announcing a comprehensive settlement with United Therapeutics that ends six legal proceedings. Liquidia will pay a net total of $380.7 million across 2026 and 2027 to United Therapeutics and other parties. The disputes involved patent infringement, alleged misuse of trade secrets and antitrust proceedings. Liquidia and United Therapeutics recorded regular-session declines of 3.11% and 1.22%, respectively.

Liquidia must pay a net $175 million within 30 business days under the settlement. Two additional installments of $72.7 million each are due by January 31, 2027, and April 30, 2027. Liquidia will also pay $60.3 million during October to parties holding rights in the antitrust proceeding involving injectable treprostinil. These payments total $380.7 million.

The settlement follows a September 30 ruling by the federal court in Delaware that two of the six asserted claims in U.S. Patent No. 11,826,327 were valid and infringed by Liquidia. The patent covers treatment of pulmonary hypertension associated with interstitial lung disease using inhaled treprostinil, including its dry-powder formulation. Following the ruling, Liquidia faced the risk of restrictions on continued marketing after United Therapeutics requested court relief that could affect product availability. The settlement resolves the dispute and requires Liquidia to abandon its appeal of the ruling.

Liquidia submitted a request to the U.S. Food and Drug Administration to remove the indication for pulmonary hypertension associated with interstitial lung disease from the Yutrepia label. Liquidia also committed to stop promoting Yutrepia for that use. The settlement preserves access to Yutrepia for patients with pulmonary arterial hypertension, the indication approved in 2025. Commercially, the agreement removes uncertainty over continued marketing for the core indication while limiting the uses Liquidia can promote.

Liquidia reported preliminary, unaudited third-quarter 2026 Yutrepia net sales of $222.7 million and cash and cash equivalents of $396.1 million at the end of September. Liquidia intends to fund the settlement through ongoing Yutrepia sales revenue and existing cash balances. These figures indicate its capacity to meet the payments, but they remain preliminary and do not replace full financial statements.

Liquidia stated that it will continue advancing Yutrepia and the L606 clinical development program according to its existing plans. L606 is an investigational sustained-release formulation of treprostinil delivered through a portable inhalation system, designed to expand treatment options for pulmonary and vascular diseases. Ending the litigation could allow management to refocus on commercialization and development, while Liquidia must absorb the settlement cost and the loss of the ability to market Yutrepia for the removed indication. The agreement includes mutual releases of claims and does not constitute an admission of liability by either company.

 
 
Top Banner
 
 

Unlock Exclusive Stock Insights!

Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.

Signup now for FREE and stay ahead of the market curve!


Why Join?

Find out what 5,000+ subscribers already know.

Real-time insights for informed decisions.

Limited slots available, SignUp Now!

 
Signup to Stocksrunner
 
 
 

Curated for you

Market Intelligence Feed

 
 

Please note that the content above should not be considered as investment advice or marketing. It does not take into account the personal data and requirements of any individual. This content is not a substitute for the reader's own judgment and should not be considered as advice or a recommendation for buying or selling any securities or financial products.

 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive Our Daily Alerts

Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Our Services

Real-time stock market updates

Expert stock analysis

Investment strategies

Top stock recommendations

Trading signals and opportunities

 
About StocksRunner

Log In

Sign Up

Plans & Pricinig

Contact Us

Terms of use

Privacy Policy

 
 
 
StocksRunner

Discover what is happening right now and piece together the key data activity before the major news outlets catch on. Stay ahead of the trends

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Subscribe to Our Daily Updates

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stocks analysis

Stocks trends

Stocks performance

Stocks analysis

Investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo